Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors

CA Stockmeier, JJ DiCarlo, Y Zhang, P Thompson and HY Meltzer

Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio.

Atypical antipsychotic drugs related to clozapine may be distinguishable from typical antipsychotic drugs by having a greater potency in vitro at serotonin2 (5-HT2) receptors relative to dopamine2 (D2) receptors. The in vivo potencies of 10 typical and 10 putative atypical antipsychotic drugs in occupying D2 and 5-HT2 receptors in rat brain are reported here. There is no significant difference in the average potency of the two groups of antipsychotic drugs in preventing the in vivo binding of N-[3H] methylspiperone to 5-HT2 receptors in the cortex. However, the average potency of the atypical antipsychotic drugs is about 8-fold less than typical antipsychotic drugs in preventing N-[3H] methylspiperone binding to D2 receptors in the striatum. Thus, all of the atypical antipsychotic drugs that are clozapine-like have a greater relative affinity in vivo for the 5-HT2 than the D2 receptor. As a group, the typical antipsychotic drugs tend to be equipotent at both receptors. The average relative potency of the group of typical antipsychotic drugs at 5-HT2 vs. D2 receptors is essentially equal when examined in vivo vs. in vitro. Atypical antipsychotic drugs are slightly but significantly more potent in vivo at D2 receptors in the olfactory tubercle than the striatum. For only the typical antipsychotic drugs, the in vivo and in vitro potencies in occupying D2 receptors are correlated with their average clinical dosage. Thus, the relative in vivo potency of clozapine-related drugs at 5-HT2 vs. D2 receptors may help identify these compounds as atypical antipsychotic drugs.

Volume 266, Issue 3, pp. 1374-1384, 09/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L. R. Gardell, K. E. Vanover, L. Pounds, R. W. Johnson, R. Barido, G. T. Anderson, I. Veinbergs, A. Dyssegaard, P. Brunmark, A. Tabatabaei, et al. ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 862 - 870. [Abstract] [Full Text] [PDF]

				R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al. Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine J Psychopharmacol, September 1, 2004; 18(3): 355 - 365. [Abstract] [PDF]

				W. L. Woolverton, R. Ranaldi, Z. Wang, G. A. Ordway, I. A. Paul, P. Petukhov, and A. Kozikowski Reinforcing Strength of a Novel Dopamine Transporter Ligand: Pharmacodynamic and Pharmacokinetic Mechanisms J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 211 - 217. [Abstract] [Full Text] [PDF]

				D. M. Weiner, E. S. Burstein, N. Nash, G. E. Croston, E. A. Currier, K. E. Vanover, S. C. Harvey, E. Donohue, H. C. Hansen, C. M. Andersson, et al. 5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 268 - 276. [Abstract] [Full Text] [PDF]

				S. Kapur, R. Zipursky, C. Jones, C. S. Shammi, G. Remington, and P. Seeman A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy Arch Gen Psychiatry, June 1, 2000; 57(6): 553 - 559. [Abstract] [Full Text] [PDF]

				T. Kuroki, H. Y. Meltzer, and J. Ichikawa Effects of Antipsychotic Drugs on Extracellular Dopamine Levels in Rat Medial Prefrontal Cortex and Nucleus Accumbens J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 774 - 781. [Abstract] [Full Text]

				S. Kapur, R. B. Zipursky, G. Remington, and H. Meltzer Do Loxapine Plus Cyproheptadine Make an Atypical Antipsychotic? PET Analysis of Their Dopamine D2 and Serotonin2 Receptor Occupancy Arch Gen Psychiatry, July 1, 1998; 55(7): 666 - 668. [Full Text] [PDF]

				G.F. Busatto and R.W. Kerwin Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia J Psychopharmacol, January 1, 1997; 11(1): 3 - 12. [Abstract] [PDF]

				H. Schoemaker, Y. Claustre, D. Fage, L. Rouquier, K. Chergui, O. Curet, A. Oblin, F. Gonon, C. Carter, J. Benavides, et al. Neurochemical Characteristics of Amisulpride, an Atypical Dopamine D2/D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 83 - 97. [Abstract] [Full Text]